Alphatec (ATEC) Q2 Revenue Jumps 27%

Alphatec (NASDAQ:ATEC) reported robust Q2 2025 results, significantly surpassing analyst expectations with GAAP revenue of $186 million, up 27.5% year-over-year, and a swing to non-GAAP profitability with EPS of $0.02 per share, compared to a loss in the prior year. Adjusted EBITDA surged 282% to $23.5 million, driven by strong surgical revenue growth, accelerated surgeon adoption of its PTP and LTP procedural families, and improved operational leverage resulting in positive free cash flow. Reflecting this strong performance and continued momentum, the company raised its full-year 2025 revenue guidance to $742 million and Adjusted EBITDA guidance to $83 million.

Analysis

Alphatec reported a strong second quarter for fiscal 2025, demonstrating significant top- and bottom-line outperformance and a pivotal swing to profitability. GAAP revenue grew 27.5% year-over-year to $186 million, comfortably exceeding the consensus estimate of $178.78 million. More notably, the company achieved non-GAAP EPS of $0.02, a stark reversal from a loss of ($0.08) in the prior-year period and well ahead of the expected loss of ($0.04). This profitability was driven by substantial operational leverage, with Adjusted EBITDA surging 282% to $23.5 million, expanding the corresponding margin to 13% from 3.8% a year ago. The growth was underpinned by a 29% increase in surgical revenue, fueled by the accelerating adoption of its PTP and LTP procedural platforms. The 21% growth in surgeon adoption is a key forward-looking indicator that supports the durability of this momentum. While non-GAAP gross margin slightly contracted by 1.3 percentage points to 69.9%, the company's ability to control operating expenses, which rose only 7%, and generate $5 million in positive free cash flow underscores improving financial discipline. Management's confidence is reflected in its raised full-year 2025 guidance, now targeting $742 million in revenue and $83 million in Adjusted EBITDA.

Key Decisions for Investors

• The strong beat-and-raise quarter, highlighted by the inflection to non-GAAP profitability and significant EBITDA margin expansion, suggests the company's growth strategy is successfully executing and may warrant a bullish reassessment of the stock.
• Investors should closely monitor forward-looking metrics such as surgeon adoption rates and procedural volume growth to validate the sustainability of the current momentum and market share gains.
• While the outlook is positive, it is prudent to track the non-GAAP gross margin for stabilization and to monitor for any escalation of the flagged tariff impacts, which could affect future profitability.